Listen to a series of short interviews with a leading expert in cataract surgery. Dr Filomena Ribeiro shares insights on the latest advances in pre-operative assessment, AI-enhanced IOL power calculation and functional depth-of-field (DOFi)-based lens selection, as well as emerging IOL materials and technologies. She also provides practical guidance on patient communication strategies to support consistent, patient-centred refractive outcomes.

The expert:

• Dr Filomena Ribeiro, Hospital da Luz Lisboa, University of Lisbon and Catholic University of Portugal, Lisbon, Portugal

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Alcon Eye Care UK Limited.

This activity is provided by touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchophthalmologyime.org/personalizing-cataract-surgery-from-pre-op-precision-to-functional-vision-outcomes/

Listen to two US-based experts as they discuss how to improve diagnostic accuracy in the USA for patients with chronic inflammatory demyelinating polyneuropathy (CIDP). They will discuss three patient cases to illustrate how to recognize and differentiate CIDP variants from other polyneuropathies, and apply key diagnostic criteria to help strengthen a diagnosis.

The experts:

• Dr Karissa Gable, Duke University, Durham, NC, USA
• Dr Jeffrey Allen, University of Minnesota, Minneapolis, MN, USA

This activity is funded by an independent medical education grant from Sanofi Genzyme.

This activity is jointly provided by USF Health and touchIME.

This activity is for HCPs in the USA only.

For further information, visit our website: https://touchneurologyime.org/cidp-diagnostics/

Listen to a series of interviews with Dr. Diana Do as she shares her expert insights into the epidemiology and quality‑of‑life burden of diabetic macular edema (DME) in the USA, outlines real‑world limitations of current anti‑VEGF–based management, and examines emerging therapies that specifically target blood–retinal barrier (BRB) dysfunction and aim to provide more durable vision protection.

The expert:

• Dr. Diana Do, Stanford University School of Medicine, Palo Alto, CA, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: www.touchOPHTHALMOLOGY.com   

Listen to Dr Teresa Alonso-Gordoa, as she evaluates the latest data on dual EZH2/AR inhibition in mCRPC and explores how emerging evidence could influence clinical decision-making in the future.

The expert

• Dr. Teresa Alonso-Gordoa - Hospital Universitario Ramón y Cajal, Madrid, Spain

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Pfizer.

This activity is provided by touchIME.

touchIME is an EBAC® accredited provider. 

For further information visit our website: www.touchONCOLOGY.com

Listen to a series of short interviews with three leading experts discussing neural-targeted therapies for dry eye disease (DED). The faculty describe the neuronal control of tear secretion, explore the mechanisms of action and clinical findings with neuromodulatory/neurostimulatory therapies for DED, and discuss how to integrate these therapies into personalized treatment plans.

The experts:

• Dr Anat Galor – Bascom Palmer Eye Institute, Miami, USA
• Dr Christopher Starr – Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, USA
• Dr Marjan Farid – University of California Irvine Medical Center, Irvine, USA

This touchPODCAST is for healthcare professionals in the USA, Canada and Latin America

This activity is funded by an independent medical education grant from Alcon Vision LLC.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchophthalmologyime.org

Listen to a series of short interviews with leading experts on computational pathology in NSCLC. The faculty, an oncologist, an oncologist-researcher and a pathologist, discuss the clinical value of computational pathology in NSCLC, review emerging tools and share practical insights on how these approaches can be applied in routine patient management.

The experts:

• Prof. Marina Garassino, University of Chicago, IL, USA
• Prof. Jakob Nikolas Kather, Technical University, Dresden and University Hospital Dresden, Germany
• Prof. Fernando Lopez-Rios, Hospital Universitario 12 de Octubre, Madrid, Spain

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from AstraZeneca.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our websites:

touchONCOLOGY: https://touchoncologyime.org/computational-pathology-in-nsclc-from-biomarker-discovery-to-clinical-integration/ touchRESPIRATORY: https://touchrespiratoryime.org/computational-pathology-in-nsclc-from-biomarker-discovery-to-clinical-integration/

Listen to a panel of leading experts discuss the future of care for patients with pancreatic ductal adenocarcinoma, or PDAC.  The faculty provide their insights on the current unmet needs, the evolving role of imaging, biomarker testing, and treatment strategies, and how these developments may impact clinical care.

The experts:

• Dr Eileen O'Reilly - Memorial Sloan Kettering Cancer Center, New York NY, United States
• Prof. Michel Ducreux - Gustave Roussy Cancer Center, Villejuif, France
• Dr Thomas Hope - University of California, San Francisco, CA, USA

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Advanced Accelerator Applications International S.A.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchONCOLOGY.com 

Listen to a series of interviews with Dr Maria-João Menéres who will provide her expert insights into the mechanisms of retinal ganglion cell (RGC) damage in both primary open-angle and secondary, steroid-induced glaucoma, and the importance of neuroprotection to mitigate the risk of glaucoma development or progression.

The expert:

• Dr Maria-João Menéres, ULS Santo António, Porto, Portugal

This touchPODCAST is for HCPs in Portugal only.

This activity is funded by an independent medical education grant from Alimera Sciences Europe Limited. The activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchOPHTHALMOLOGY.com   

Listen as Prof. Sumit (Sam) Garg shares expert clinical insights on how AI-supported biometric analysis can increase refractive accuracy and support confident presbyopia-correcting IOL selection, including which patient and ocular characteristics are most likely to benefit from AI-based tools. He also outlines practical strategies for structuring preoperative counselling to set realistic expectations and improve patient satisfaction through clear, effective communication.

The expert:

• Prof. Sumit (Sam) Garg, University of California, Irvine, CA, USA

This touchPODCAST is for HCPs outside of the UK.

This educational activity is funded by an independent medical education grant from Johnson & Johnson Surgical Vision, Inc.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchophthalmology.org

The experts

• Dr Jorge Cortes, Georgia Cancer Center, Augusta, GA, USA
• Dr Elias Jabbour, MD Anderson Cancer Center, Houston, TX, USA 
• Dr Vivian Oehler, Fred Hutch Cancer Center, Seattle, WA, USA

This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Takeda Development Center Americas, Inc. Jointly provided by Partners for Advancing Clinical Education and touchIME. For further information, visit our websites:  www.touchHAEMATOLOGY.com www.touchONCOLOGY.com

Listen to a series of short interviews with paediatric endocrinologist Dr Ashley Shoemaker as she discusses the clinical manifestations and pathophysiology of Prader–Willi syndrome (PWS), with a focus on hyperphagia by exploring the spectrum across the lifespan of PWS and shares best practices for managing PWS-related hyperphagia within a multidisciplinary framework.

The expert:

• Dr Ashley Shoemaker, Vanderbilt University Medical Center, Nashville, TN, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Soleno Therapeutics.

The activity is jointly provided by Partners for Advancing Clinical Education (Partners) and touchIME.

For further information, visit our website: https://touchendocrinologyime.org/hyperphagia-pws-recognition-management/

Listen to leading experts discuss the role of antibody–drug conjugates (ADCs) in NSCLC with brain metastases, including the latest clinical trial evidence, practical approaches to patient selection and treatment sequencing alongside local CNS therapies, and the evolving pipeline of investigational ADCs.

The expert(s)

• Dr Lyudmila Bazhenova, Moore’s Cancer Center, San Diego, CA, USA
• Dr Elvire Pons-Tostivint, Nantes Université, Centre Hospitalier Universitaire Nantes, France
• Dr Julia Rotow, Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs only outside of the UK. This activity is funded by an independent medical education grant fromAstraZeneca. This activity is jointly provided by USF Health and touchIME.  touchIME is an EBAC® accredited provider.

For further information visit our websites: 

www.touchONCOLOGY.com www.touchRESPIRATORY.com

Listen to a panel of leading experts as they explore the latest advances in PNH pathophysiology, diagnostic approaches and therapeutic strategies, including data from ASH 2025, with practical insights for contemporary clinical practice.

The experts:

• Prof. Bruno Fattizzo, Università degli Studi di Milano, Milan, Italy
• Dr Austin Kulasekararaj, King’s College Hospital NHS Foundation Trust, London, UK
• Dr Srikanth Nagalla, Miami Cancer Institute, Miami, FL, USA

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Alexion Pharma GmbH.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

Listen to two experts as they discuss three cases illustrating the heterogeneous, multisystem nature of late-onset Pompe disease (LOPD). They examine key decision points from recognizing early clinical clues and confirming diagnosis to optimizing enzyme replacement therapy (ERT), monitoring progression and coordinating multidisciplinary, patient-centred care. 

The experts:

• Prof. John Vissing, University of Copenhagen, Copenhagen, Denmark
• Prof. Pascal Laforêt, Versailles-Saint Quentin University, Versailles, France 

This activity is for HCPs outside of the USA.

This activity is supported by an independent educational grant from Amicus Therapeutics UK LTD.

touchIME is an EBAC® accredited provider.

For further information visit our websites: 

touchNEUROLOGY -  https://touchneurologyime.org/diagnosis-monitoring-management-lopd/ touchCARDIO - https://touchcardioime.org/diagnosis-monitoring-management-lopd/ touchENDOCRINOLOGY - https://touchendocrinologyime.org/diagnosis-monitoring-management-lopd/ touchRESPIRATORY - https://touchrespiratoryime.org/diagnosis-monitoring-management-lopd/

Listen to multiple myeloma expert Dr Rakesh Popat review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the International Multiple Society (IMS) and American Society of Hematology (ASH) 2025 congresses. Dr Popat is then joined by fellow experts Dr Paula Rodríguez-Otero and Dr Roberto Mina to discuss the implications of these data for current and future clinical practice.

Overview

• Data reviews with Dr Popat
• Expert panel discussions with Dr Popat, Dr Rodríguez-Otero and Dr Mina on the themes below

Clinical themes

• Approved BCMA-directed therapeutic approaches 
• Practical application of BCMA-directed therapies
• Future of treating RRMM: Emerging BCMA-directed therapies and combinations

The internationally renowned multiple myeloma expert faculty

• Dr Rakesh Popat: London, UK

• Dr Paula Rodríguez-Otero: Pamplona, Spain
• Dr Roberto Mina: Atlanta, GA, USA

This touchPODCAST is for HCPs outside of the USA. 

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets

In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Module 3: Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers

In this module, Professor Pasi Jänne and Professor Paul Hofman explore how precision medicine and molecular resistance mechanisms are shaping testing strategies. They discuss the role of biomarkers, evolving guideline recommendations and how clinicians can adapt testing approaches to align with new targeted therapies.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Paul Hofman, University Côte d’Azur, Nice, France.

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:  

https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/

https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/

Listen to insights from Dr Kathleen Moore on the pathophysiology and molecular features of low-grade serous ovarian cancer (LGSOC) and how it differs from other ovarian cancers. She also discusses evidence-based treatment options and sequencing, as well as practical considerations relating to administration and side-effect management.

The expert:

• Dr Kathleen Moore, OH Health Stephenson Cancer Center, Oklahoma City, OK, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Verastem, Inc.

The activity is jointly provided by Partners for Advancing Clinical Education and touchIME.

For further information visit our website: www.touchONCOLOGY.com

The presence of anaemia and/or thrombocytopenia complicates the management of patients with myelofibrosis (MF). Listen to expert haematologists consider the burden of cytopenias in patients with MF and discuss strategies to reduce transfusion dependence, improve splenomegaly and personalize treatment with JAK inhibitors.

The experts

• Prof. Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
• Dr Laura Fox, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

This touchPODCAST is for HCPs outside of the USA.

This activity is supported by an independent medical education grant from GSK.

This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP).

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchHAEMATOLOGY.com

The experts:

• Dr Delphine Rea, Hôpital Saint-Louis, Paris, France 
• Prof. Andreas Hochhaus, Jena University Hospital, Jena, Germany
• Prof. Etab Atallah, Medical College of Wisconsin, Milwaukee, WI, USA

This activity is for healthcare professionals outside of the USA and UK. This independent medical education is supported by Novartis and is provided by touchIME. For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

Listen to Dr Christine Bestvina, as she evaluates the latest data on KRAS mutations in NSCLC and explores how emerging evidence for targeted therapies could influence clinical decision-making.

The expert

• Dr Christine Bestvina, University of Chicago, Chicago, IL, USA

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Revolution Medicines.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider. 

For further information visit our website: www.touchONCOLOGY.com

Listen to a series of short interviews with four leading experts as they discuss the role of HER2 as a targetable biomarker in BTC and GEA. They examine the present treatment landscape for HER2-positive BTC and GEA and evaluate clinical implications of recent approvals and advances in current and emerging HER2-targeting therapies for HER2-positive BTC and GEA. 

The experts

• Prof. Thomas Seufferlein, Ulm University, Ulm, Germany
• Dr Elizabeth Smyth, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
• Prof. Florian Lordick, University of Leipzig, Leipzig, Germany
• Prof. Eric Van Cutsem, University of Leuven, Leuven, Belgium

This touchPODCAST is for HCPs outside of the UK

This activity is supported by an independent educational grant from Jazz Pharmaceuticals. 

Jointly provided by Partners for Advancing Clinical Education and touchIME. 

touchIME is an EBAC® accredited provider. 

For further information visit our website: 

www.touchONCOLOGY.com

Listen to a panel of leading experts discuss the optimal management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs), with a focus on peptide receptor radionuclide therapy (PRRT). The faculty provide their insights on the current state of the art, the evolving role of PRRT in GEP-NET treatment, and recent data with existing and emerging PRRT agents. The faculty will also consider future developments in this field, including personalized approaches to PRRT, and how they might impact clinical care.

The experts:

• Prof. Thorvardur Halfdanarson, Mayo Clinic Rochester, MN, USA
• Prof. Rocio Garcia-Carbonero, Hospital Universitario 12 de Octubre, Madrid, Spain
• Prof. Nicola Fazio, European Institute of Oncology, Milan, Italy

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from ITM Isotope Technologies Munich SE.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our websites: www.touchONCOLOGY.com and www.touchENDOCRINOLOGY.com

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets

In this module, Professor Pasi Jänne and Dr Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:  

https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/

https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/

Listen to a series of interviews with two medical retina specialists and a biomarker expert who will provide their insights into the pathophysiology of diabetic macular oedema (DMO), including the inflammatory mechanisms of disease and how they may impact treatment. The faculty will also consider the clinical utility of optical coherence tomography (OCT) imaging biomarkers and emerging evidence on the evolving role of corticosteroids in the management of DMO.

The experts:

• Prof. Stela Vujosevic, Medical Retina Unit, IRCCS MultiMedica and University of Milan, Milan, Italy
• Prof. Francesco Bandello, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy
• Prof. Laurent Kodjikian, University of Lyon and Croix-Rousse University Hospital, Lyon, France

This touchPODCAST is for HCPs outside of the UK and USA.

This activity is funded by an independent medical education grant from Alimera Sciences Europe Ltd. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchOPHTHALMOLOGY.com

Listen to a panel of experts in epilepsy as they discuss how to promptly and accurately diagnose and manage Lennox–Gastaut syndrome (LGS). Moderated by a leading European expert, this episode brings together faculty from the Gulf region and Japan, as they explore diagnostic approaches in their regions, before sharing their unique regional perspectives and real-world experience in caring for patients with LGS.  

The experts

• Prof. Nicola Specchio: Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
• Dr Raidah Al-Baradie: King Fahad Specialist Hospital, Dammam, Saudi Arabia
• Dr Taoufik Alsaadi: American Center for Neurology, Abu Dhabi, Dubai, UAE
• Prof. Eiji Nakagawa: National Center of Neurology and Psychiatry, Tokyo, Japan
• Prof. Hideo Yamanouchi: Saitama Medical University, Saitama, Japan

Chapters

• The disease state of LGS (00:00–18:47)
• Managing patients with LGS in the Gulf (18:48–37:00)
• Managing patients with LGS in Japan (37:01–56:25)

This touchPODCAST is for HCPs outside of the UK only. 

This activity is supported by an independent medical educational grant from Jazz Pharmaceuticals. 

Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider.

For further information visit: touchneurologyime.org/diagnosis-treatment-lennox-gastaut-syndrome/

Listen to short interviews with two expert cardiologists discussing the role of current and emerging therapeutic classes that aim to address the unmet needs of patients with hypertrophic cardiomyopathy. The faculty will review current therapeutic approaches for managing obstructive versus nonobstructive hypertrophic cardiomyopathy to highlight existing gaps in patient care. They will then discuss the latest data for emerging therapeutic classes and consider how they may address patients’ unmet needs in the future.   

The experts

• Dr Martin Maron, Lahey Hospital & Medical Center, Burlington, MA, USA
• Dr Michelle Michels, Erasmus MC, Rotterdam, The Netherlands

This touchPODCAST is for healthcare professionals outside of the UK.

This activity is supported by an independent medical educational grant from Cytokinetics, Inc.

Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchcardio.com/

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:  

touchONCOLOGY: https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/

touchRESPIRATORY: https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/

• Prof. Jean-Pascal Machiels, Cliniques universitaires Saint-Luc, Brussels, Belgium

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com

Listen to two experts as they discuss the diagnosis, treatment and how to support patients with FCS. They cover how to recognize key clinical signs and symptoms, strategies to help manage symptoms, reduce triglyceride levels and prevent complications. They  also share key insights from their experience with novel targeted therapies for FCS.

The expert(s)

• Professor Antonio Gallo, Sorbonne University Hospital Pitié-Salpêtrière, Paris, France
• Dr Vikesh Singh, Johns Hopkins University School of Medicine, Baltimore, MD, USA

This touchPODCAST is for HCPs in the USA and Europe only.

This activity is funded by an independent medical education grant from Arrowhead Pharmaceuticals, Inc.

This activity is jointly provided by USF Health and touchIME. 

touchIME is an EBAC® accredited provider.

For further information visit our websites: https://touchcardioime.org/fcs-unmasked/ and https://touchendocrinologyime.org/fcs-unmasked/

Prof. Lucia de Franceschi, a leading expert in sickle cell disease, examines the clinical manifestations and burden of the condition, reviews current and emerging treatments and offers guidance on comprehensive lifespan care that addresses complications, quality of life, and disparities, while highlighting the essential role of multidisciplinary support.

The experts

• Prof. Lucia de Franceschi, University of Verona, Italy

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Agios Pharmaceuticals, Inc.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchHAEMATOLOGY.com

• Dr Raphael Schiffmann, Texas Christian University, Fort Worth, TX, USA
• Ms Dawn Laney, Emory Genetic Clinical Trials Center, Atlanta, GA, USA
• Dr Ozlem Goker-Alpan, Lysosomal Disorders Research and Treatment Center (LDRTC), Fairfax, VA, USA

This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Amicus Therapeutics Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our websites:  www.touchENDOCRINOLOGY.com www.touchCARDIO.com and www.touchNEUROLOGY.com

Listen to three experts as they discuss how patient and disease characteristics may inform treatment selection in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). They will discuss the cases of three patients which will cover first-line and second-line treatments as well as key considerations for their treatment plans in their patients' cases.

The experts:

• Dr Nabil Saba, Winship Cancer Institute, Emory University, Atlanta, GA, USA
• Dr Victoria Villaflor, Chao Family Comprehensive Cancer Center, UCI Health, Orange, CA, USA

This activity is for HCPs in the USA only

This activity is funded by an independent medical education grant from Coherus Biosciences.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/treatment-selection-in-r-m-npc/

Listen to a series of short expert interviews on the role of B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM). The faculty discuss patient selection, treatment tailoring and strategies to manage side effects, providing practical guidance for integrating BCMA-targeting approaches into care.

The experts

• Prof. Jesús San Miguel, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
• Prof. Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, The Netherlands
• Dr Francesca Gay, University of Torino, Italy

This touchPODCAST is for HCPs outside of the USA.

This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our websites: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com 

Listen to a series of short interviews with leading experts on phacoemulsification in cataract surgery. The faculty discuss optimizing fluidics and ultrasound energy, ophthalmic viscosurgical device selection, and integrating technological advances in phacoemulsification into clinical practice.

The experts:

• Dr Ike K Ahmed, Prism Eye Institute, Toronto, ON, Canada; John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA
• Dr David F Chang, University of California, San Francisco, CA, USA; Altos Eye Physicians, Los Altos, CA, USA
• Dr Jennifer Loh, Loh Ophthalmology Associates, Miami, FL, USA

This touchPODCAST is for HCPs in the USA, Latin America and Canada only.

This activity is funded by an independent medical education grant from Alcon Vision, LLC and Johnson & Johnson Surgical Vision, Inc.

The activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchophthalmologyime.org/phacoemulsification-cataract-surgery/

Listen to a series of interviews with Prof. Elias Traboulsi on the clinical presentation, diagnosis and management of patients with Stargardt disease. Prof. Traboulsi shares key clinical characteristics and retinal imaging results indicative of Stargardt disease, discusses the right tools to use to accurately and promptly diagnose the condition, and reviews supportive care strategies to maximize patients’ functional vision and improve their wellbeing. 

The expert:

• Prof. Elias Traboulsi, Cleveland Clinic, Cleveland, OH, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Alkeus Pharmaceuticals, Inc.

The activity is jointly provided by USF Health and touchIME.

For further information visit our website: www.touchOPHTHALMOLOGY.com

• Prof. Jennifer Sherr, Yale School of Medicine, New Haven, CT, US

This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Abbott Diabetes Care Inc. This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.  For further information visit our website:  www.touchENDOCRINOLOGY.com

This touchCASES activity presents expert-led discussions exploring three clinical cases of pulmonary arterial hypertension (PAH). Through these detailed cases, the expert faculty examine a range of clinical presentations and highlight critical decision points across the patient journey, from initial diagnosis and risk stratification to treatment initiation and escalation.

The experts:

• Dr Athénaïs Boucly, University of Paris-Saclay, Le Kremlin-Bicêtre, Paris, France
• Prof. Pilar Escribano Subìas, Complutense University of Madrid, Spain

This touchPODCAST is for HCPs outside the UK

This activity is provided by an independent medical education grant from Merck Sharp & Dohme LLC. The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider

For further information, visit our websites: www.touchRESPIRATORY.com and www.touchCARDIO.com

Listen to two experts discuss how continuous glucose monitoring (CGM) can help identify and manage cardiovascular risk in people with or without diabetes. They explore the role of glycaemic variability, the limitations of conventional glucose metrics, and the added value of CGM, including recent advances and patient education to support effective use.

The experts:

• Dr Eden Miller, Diabetes and Obesity Care, Bend, OR, USA
• Dr Ian J Neeland, Case Western Reserve University, and Harrington Heart and Vascular Institute, University Hospitals Cleveland, OH, USA

This activity is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Abbott Diabetes Care Inc.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchCARDIO.com and www.touchENDOCRINOLOGY.com

Listen to a series of short interviews with three leading experts as they discuss the use of HER2 as a targetable biomarker in gastrointestinal oncology. The faculty cover the clinical significance of HER2 alterations, best practices for biomarker testing, key clinical trial data on efficacy and safety, and the role of HER2-targeted therapies in both common and rare GI cancers. They also address retesting at progression, management of adverse events, and emerging treatment approaches.

The experts

• Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, New York, NY, USA
• Prof. Eric Van Cutsem, University of Leuven, Leuven, Belgium
• Prof. Florian Lordick, University of Leipzig, Leipzig, Germany

This touchPODCAST is for HCPs outside of the UK

This activity is funded by an independent medical education grant from AstraZeneca. 

This activity is jointly provided by USF Health and touchIME.  touchIME is an EBAC® accredited provider. 

For further information visit our website:  www.touchONCOLOGY.com 

Listen to three leading international experts in gynaecological oncology as they discuss how immunotherapy is transforming the treatment of advanced endometrial carcinoma. The faculty explore how the latest data are shaping first-line treatment decisions, how to personalize therapy using biomarkers and molecular classification, and how to manage immune-related adverse events through practical monitoring strategies.

The experts

• Prof. Isabelle Ray-Coquard, Centre Léon Bérard, Lyon, France
• Prof. Nicoletta Colombo, University of Milan-Bicocca, Milan, Italy
• Dr Brian Slomovitz, Mount Sinai Medical Center, Miami, FL, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/panel-icis-in-ec/ 

Listen to Dr Chafic Karam share expert insights on diagnosing and managing ATTRv amyloidosis. In this short interview, he covers red-flag symptoms, diagnostic challenges and key strategies for differentiating ATTRv. He also discusses current treatment options, including TTR stabilisers and gene silencers, as well as emerging therapies aimed at improving patient outcomes.

The expert:

• Dr Chafic Karam, University of Pennsylvania, Philadelphia, PA, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our websites: 

https://touchneurology.com/ and https://touchcardio.com/

Listen to multiple myeloma expert Prof. Philippe Moreau review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy), American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) 2025 congresses. Prof. Moreau is then joined by fellow experts Dr Paola Neri and Prof. Hermann Einsele to discuss how these data may apply in clinical practice.

Overview

• Data reviews with Prof. Moreau
• Expert panel discussions with Prof. Moreau, Dr Neri and Prof. Einsele on the themes below

Clinical themes

• Approved BCMA-directed therapeutic approaches 
• Practical application of BCMA-directed therapies
• Future of treating RRMM: Emerging BCMA-directed therapies and combinations

The internationally renowned multiple myeloma expert faculty

• Prof. Philippe Moreau: Nantes, France

• Prof. Hermann Einsele: Würzburg, Germany

• Dr Paola Neri: Calgary, AB, Canada

This touchPODCAST is for HCPs outside of the USA. 

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

The expert:

• Prof. Ilona Frieden, University of California, San Francisco, CA, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Pierre Fabre Pharmaceuticals, Inc. This activity is jointly provided by USF Health and touchIME in collaboration with our education partner, Pediatric Dermatology Research Alliance (PeDRA). For further information visit our website:

https://touchdermaime.org/

Listen to two oncologists discuss the incorporation of antibody–drug conjugates (ADCs) into the treatment of metastatic breast cancer, tackling questions submitted by the oncology community. They discuss how treatment can be guided by biomarkers, give practical insights into creating a personalized care plan for patients, and share strategies for managing ADC-associated toxicities.

The experts

• Prof. Giuseppe Curigliano, European Institute of Oncology and University of Milan, Italy
• Dr Alison Conlin, Providence Cancer Institute, Portland, OR, USA

This touchPODCAST is for HCPs outside of the UK. 

This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchoncologyime.org/adcs-in-the-treatment-of-mbc/

Listen to a series of short interviews with three leading experts discussing the application of immunotherapy in triple-negative breast cancer (TNBC). The experts explore the latest data and guideline recommendations for immunotherapy in early-stage and metastatic TNBC, and how to maximize treatment benefits. 

The experts:

• Prof. Sherko Kümmel – Kliniken Essen-Mitte, Essen, Germany
• Prof. Rebecca Dent – National Cancer Center Singapore, Singapore
• Prof. Peter Schmid – Barts Cancer Institute, London, UK

This touchPODCAST is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:

https://touchoncologyime.org/management-of-tnbc-with-immunotherapy/

Listen to Prof. Jonathan Spicer share expert insights on immunotherapy in early-stage non-small cell lung cancer (NSCLC). He explores current treatment strategies, highlights the role of neoadjuvant, perioperative and adjuvant approaches, and considers practical aspects of clinical implementation.

The expert

• Prof. Jonathan Spicer, McGill University, Montreal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchrespiratoryime.org/touchexpert-focus-immunotherapy-early-stage-nsclc/

Listen to Prof. Jonathan Spicer share expert insights on immunotherapy in early-stage non-small cell lung cancer (NSCLC). He explores current treatment strategies, highlights the role of neoadjuvant, perioperative and adjuvant approaches, and considers practical aspects of clinical implementation.

The expert

• Prof. Jonathan Spicer, McGill University, Montreal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchoncologyime.org/touchexpert-focus-immunotherapy-early-stage-nsclc/

Listen to  Prof. José Arribas, a leading HIV expert, and Ms Harriet Langanke, a journalist and HIV activist, discuss personalized care strategies for people living with HIV, focusing on three key concerns: weight gain, pill fatigue and treatment initiation.

The experts:

• Prof. José Arribas, University Hospital La Paz, Madrid, Spain,
• Ms Harriet Langanke, GSSG, Cologne, Germany

This touchPODCAST is for HCPs outside of the UK

This activity is funded by an independent medical education grant from Viiv Healthcare. This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchinfectiousdiseases.com

In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC.

The expert:

• Dr Christine Bestvina - University of Chicago, Chicago, IL, USA

This touchPODCAST is for HCPs outside the UK.  This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchrespiratory.com

In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC.

The expert:

• Dr Christine Bestvina - University of Chicago, Chicago, IL, USA

This touchPODCAST is for HCPs outside the UK. 

This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchoncology.com

Listen to Dr Laura Periman share expert insights on dry eye disease. In this episode, she explores the pathophysiological mechanisms behind the condition, highlights key diagnostic tools, reviews current treatment options—including exciting advances in neuromodulation therapies—and discusses emerging targeted approaches shaping clinical management today.

The expert

• Dr Laura Periman, Periman Eye Institute, Seattle, WA, USA

This touchPODCAST is for HCPs outside of the UK. 

This activity is funded by an independent medical education grant from Alcon Vision, LLC.

The activity is jointly provided by USF Health and touchIME. 

For further information, visit our website: https://touchophthalmologyime.org/advances-in-dry-eye-disease/

Listen to two experts in geographic atrophy (GA) discuss recent advances in the care of patients. They explore the importance of early identification of GA and how this can be achieved, examine the potential impact of new and emerging therapies for GA, and highlight key practical considerations for monitoring treatment outcomes and evaluating effectiveness of therapy in clinical practice. 

The experts

• Prof. Giuseppe Querques, IRCCS Hospital San Raffaele, Milan, Italy
• Dr Arshad M. Khanani, Sierra Eye Associates, Reno, NV, USA

This touchPODCAST is for HCPs outside of the UK. 

This activity is funded by an independent medical education grant from Astellas Pharma Inc.

The activity is jointly provided by USF Health and touchIME.  touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchophthalmologyime.org/

Join Prof. Montalban as he shares expert insights into the pathophysiology of progressive MS and the rationale for targeting BTK inhibitors. He reviews emerging clinical data supporting the use of BTK inhibitors and discusses how they may fit into the evolving treatment landscape. In this context, Prof. Montalban also considers current guideline-recommended therapies for progressive MS and highlights key areas of remaining unmet treatment need.

The expert

Prof. Xavier Montalban, Centre d'Esclerosi Múltiple de Catalunya (Cemcat) and Vall d'Hebron University Hospital, Barcelona, Spain

This touchPODCAST is for HCPs outside of the UK only.

This activity is provided by an independent medical education grant from Sanofi. 

The activity is jointly provided by USF Health and touchIME. 

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchneurology.com/ 

Listen to two expert neurologists and a neurology nurse as they explore the role of neonatal Fc receptor (FcRn) inhibitors in improving the burden of disease in patients with generalized myasthenia gravis. The faculty will consider how the burden of disease and treatment in patients with generalized myasthenia gravis can be used to inform treatment decisions, the latest clinical data for FcRn inhibitors and the best practice strategies for using FcRn inhibitors in clinical practice. 

The experts

• Prof. Michael Nicolle – Western University and London Health Sciences Centre, London, ON, Canada
• Dr Karissa Gable – Duke University, Durham, NC, USA
• Ms Missy Pittman – Duke University, Durham, NC, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Argenx and UCB, Inc. 

The activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchneurologyime.org/reducing-burden-of-disease-in-gmg-exploring-the-role-of-fcrn-inhibitors/

The multidisciplinary team

• Endocrinologist: Prof Tina Vilsbøll
• Primary Care Physician: Dr Gihane Zarifa
• Nurse specialist: Ms. Lori Berard
• Patient advocate: Mr. Ostap Soroka

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/

The multidisciplinary team

• Endocrinologist: Prof Tina Vilsbøll
• Primary Care Physician: Dr Gihane Zarifa

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/

The multidisciplinary team

• Endocrinologist: Prof Tina Vilsbøll
• Primary Care Physician: Dr Gihane Zarifa
• Patient advocate: Mr. Ostap Soroka

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/

Listen to this touchSYMPOSIUM recorded live in March 2025 at the The European Lung Cancer Congress in Paris, France.

Symposium chair Prof. Marina Garassino is joined by Prof. Jarushka Naidoo and Prof. David Planchard to explore the evolving role of TROP2-targeted ADCs in NSCLC.  Session 1: Prof. Marina Garassino highlights the emergence of TROP2 in NSCLC as a promising area of therapeutic innovation

Session 2: Prof.  Jaruska Naidoo discusses the latest clinical trial findings for TROP2-targeting ADCs in NSCLC Session 3: Prof. David Planchard discusses the complexities of using TROP2 as a biomarker for patient selection

Session 4: A panel discussion offering practical approaches for managing adverse effects associated with TROP2-targeted ADCs in clinical practice, with Q&A.

This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Daiichi Sankyo and AstraZeneca and is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/

Listen to a panel of world-leading experts in lysosomal storage disorders  explore treatment needs along the lifespan of people living with alpha-mannosidosis, discuss the evolving treatment landscape, and finally, reflect on how treatment advances may be integrated into the multidisciplinary management of alpha-mannosidosis, with the aim of optimizing patient outcomes.

The experts

• Dr Barbara K. Burton, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
• Dr Can Ficicioglu, Children's Hospital of Philadelphia, PA, USA
• Dr Christina Lampe, University of Giessen, Giessen, Germany

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Chiesi USA, Inc. 

The activity is jointly provided by USF Health and touchIME. 

For further information visit: touchneurologyime.org/

Listen to a panel of world-leading experts in lysosomal storage disorders  explore treatment needs along the lifespan of people living with alpha-mannosidosis, discuss the evolving treatment landscape, and finally, reflect on how treatment advances may be integrated into the multidisciplinary management of alpha-mannosidosis, with the aim of optimizing patient outcomes.

The experts

• Dr Barbara K. Burton, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
• Dr Can Ficicioglu, Children's Hospital of Philadelphia, PA, USA
• Dr Christina Lampe, University of Giessen, Giessen, Germany

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Chiesi USA, Inc. 

The activity is jointly provided by USF Health and touchIME. 

For further information visit: touchendocrinologyime.org/

Listen to two expert gynaecologic oncology specialists discuss the evolving role of immunotherapy in the treatment of advanced/recurrent endometrial cancer. They explore how immune checkpoint inhibitors are reshaping standards of care across lines of therapy, highlight key practical considerations for optimizing patient selection and management, and examine emerging data that may influence future treatment paradigms.

The experts

• Dr Alexandra Leary, Gustave Roussy Cancer Center, Villejuif, France
• Dr Juan Francisco Grau, Gustave Roussy Cancer Center, Villejuif, France

This touchPODCAST is for HCPs outside of the USA and UK only. 

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/ 

Listen to three experts as they explore the burden of myelofibrosis and anaemia and/or thrombocytopenia, discuss targeted treatment strategies and how to maximize benefits for patients.

The experts

• Prof. Haifa Kathrin Al-Ali – University Hospital of Halle, Halle (Saale), Germany
• Prof. Jean-Jacques Kiladjian – Université Paris Cité and Saint-Louis Hospital, Paris, France
• Prof. Alessandro Vannucchi – University of Florence, Florence, Italy

This touchPODCAST is for HCPs outside of the UK and USA only.

This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME.  touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchhaematologyime.org/ 

The multidisciplinary team

• Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France
• Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA
• Clinical oncology pharmacy specialist: Dr Scott Edwards, Dr. H. Bliss Murphy Cancer Center, St. John’s, Newfoundland, Canada

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchONCOLOGY.com

The multidisciplinary team

• Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France
• Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA
• Patient advocate: Mrs Lesley Turner, Independent Cancer Patients’ Voice, UK

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchONCOLOGY.com

The multidisciplinary team

• Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France
• Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchONCOLOGY.com

Listen to retina specialist Prof. Peter Kaiser answer a series of questions on the current clinical landscape for neovascular age-related macular degeneration and diabetic macular oedema, share his perspective on how newly available treatments are influencing the existing standard of care and provide guidance on how new therapies can be effectively integrated into clinical practice.

The expert

• Prof. Peter Kaiser, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA

This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from Bayer Consumer Care AG. The activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchophthalmologyime.org/adopting-emerging-therapies-for-retinal-diseases

Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

Overview

•       Data reviews with Prof. Mozaffar,
•       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

Clinical themes

1. Clinical and real-world data on long-term outcomes in Pompe disease
2. Outcomes and impact of treatment switching in Pompe disease
3. Latest clinical data on current and emerging therapies in Pompe disease

The internationally renowned Pompe disease expert faculty

•       Prof. Tahseen Mozaffar, Irvine, CA, USA
•       Dr Jennifer L Cohen, Durham, NC, USA
•       Prof. Benedikt Schoser, Munich, German

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:

Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

Overview

•       Data reviews with Prof. Mozaffar,
•       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

Clinical themes

1. Clinical and real-world data on long-term outcomes in Pompe disease
2. Outcomes and impact of treatment switching in Pompe disease
3. Latest clinical data on current and emerging therapies in Pompe disease

The internationally renowned Pompe disease expert faculty

•       Prof. Tahseen Mozaffar, Irvine, CA, USA
•       Dr Jennifer L Cohen, Durham, NC, USA
•       Prof. Benedikt Schoser, Munich, Germany

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Amicus Therapeutics.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:

Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

Overview

•       Data reviews with Prof. Mozaffar,
•       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

Clinical themes

1. Clinical and real-world data on long-term outcomes in Pompe disease
2. Outcomes and impact of treatment switching in Pompe disease
3. Latest clinical data on current and emerging therapies in Pompe disease

The internationally renowned Pompe disease expert faculty

•       Prof. Tahseen Mozaffar, Irvine, CA, USA
•       Dr Jennifer L Cohen, Durham, NC, USA
•       Prof. Benedikt Schoser, Munich, Germany

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Amicus Therapeutics.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:

Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

Overview

•       Data reviews with Prof. Mozaffar,
•       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

Clinical themes

1. Clinical and real-world data on long-term outcomes in Pompe disease
2. Outcomes and impact of treatment switching in Pompe disease
3. Latest clinical data on current and emerging therapies in Pompe disease

The internationally renowned Pompe disease expert faculty

•       Prof. Tahseen Mozaffar, Irvine, CA, USA
•       Dr Jennifer L Cohen, Durham, NC, USA
•       Prof. Benedikt Schoser, Munich, Germany

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Amicus Therapeutics.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:

Listen to experts Dr Alicia Morgans, Dr Grace Cullen, and patient advocate, Mr Tony Collier, discuss the importance and practicalities of engaging patients in their care and hear insights from the perspective of a patient advocate in relation to the use of PARP inhibitors.

The multidisciplinary team and patient advocate:

Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Nurse practitioner – Dr Grace Cullen

John D. Dingell VA Medical Center, Detroit, Michigan, USA

Patient Advocate – Mr Tony Collier Tackle Prostate Cancer, London, UK

This touchPODCAST is for HCPs outside of the UK only.

This activity is supported by an independent medical education funding request from AstraZeneca.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen.  

The multidisciplinary team:

Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA

Pathologist – Prof. Albrecht Stenzinger University of Heidelberg, Heidelberg, Germany

This touchPODCAST is for HCPs outside of the UK  only.

This activity is supported by an independent medical education funding request from AstraZeneca.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC

Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC).

The multidisciplinary team:

Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA

This touchPODCAST is for HCPs outside of the UK  only.

This activity is supported by an independent medical education funding request from AstraZeneca.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

• Dr Sue Pedersen, University of Calgary, Calgary, Canada
• Prof. Carel le Roux, University College Dublin, Dublin, Ireland
• Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA

This touchPODCAST is for healthcare professionals outside of the USA and UK. This activity is funded by an independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website: 

www.touchCARDIO.com

The experts

• Dr Sue Pedersen, University of Calgary, Calgary, Canada
• Prof. Carel le Roux, University College Dublin, Dublin, Ireland
• Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA

This touchPODCAST is for healthcare professionals outside of the USA and UK. This activity is funded by an independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. 

For further information visit our website: 

www.touchENDOCRINOLOGY.com

Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations.

The experts

• Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
• Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany
• Dr Sonia Pernas: Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

This touchPODCAST is for healthcare professionals outside of the UK and the USA.

This activity is funded by an independent medical education grant from Novartis.

This activity is provided by touchIME.

For further information visit our website: 

www.touchONCOLOGY.com

• Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
• Dr Marc Steben, HPV Global Action and Université de Montréal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchoncologyime.org/in-conversation-improving-hpv-vaccine-uptake/

• Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
• Dr Marc Steben, HPV Global Action and Université de Montréal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchinfectiousdiseasesime.org/in-conversation-improving-hpv-vaccine-uptake/

In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies.

The expert:

• Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs outside the UK.  This activity is funded by an independent medical education grant from Sanofi US. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies.

The expert:

• Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs outside the UK.  This activity is funded by an independent medical education grant from Sanofi US. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchHAEMATOLOGY.com

Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. 

The experts

• Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA
• Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic

This touchPODCAST is for HCPs outside of the USA and UK.

This activity is funded by an independent medical education grant from GSK. 

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchoncologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/

Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. 

The experts

• Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA
• Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic

This touchPODCAST is for HCPs outside of the USA and UK.

This activity is funded by an independent medical education grant from GSK. 

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchhaematologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/

Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes.

The experts

• Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
• Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

This touchPODCAST is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Revolution Medicines.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchoncologyime.org/mutations-and-personalized-cancer-care-targeting-the-future/

Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.  

The experts

• Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA
• Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK
• Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi.

This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider.

For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#

Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.  

The experts

• Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA
• Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK
• Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi.

This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider.

For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#

Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future.

The expert

• Prof. Céline Mascaux, Strasbourg University, Strasbourg, France

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:  www.touchrespiratory.org/ADCs-in-NSCLC

Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future.

The expert

• Prof. Céline Mascaux, Strasbourg University, Strasbourg, France

This touchPODCAST is for HCPs only

This activity is funded by an independent medical education grant from AstraZeneca.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchoncology.org/ADCs-in-NSCLC

Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA. 

Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies.

• Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life 
• Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current management strategies 
• Session 3: Prof. David Kuter reviews emerging targeted treatment options for ITP, with a focus on their mechanisms of action and the latest data 
• Session 4: A panel discussion with all three faculty on shared decision-making and collaboration in the clinic 

This touchPODCAST is for HCPs in the USA.

This activity is funded by an independent medical education grant from Sanofi.

This activity is jointly provided by USF Health and touchIME. 

For further information visit our website: touchoncologyime.org

Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA. 

Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies.

• Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life 
• Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current management strategies 
• Session 3: Prof. David Kuter reviews emerging targeted treatment options for ITP, with a focus on their mechanisms of action and the latest data 
• Session 4: A panel discussion with all three faculty on shared decision-making and collaboration in the clinic 

This touchPODCAST is for HCPs in the USA.

This activity is funded by an independent medical education grant from Sanofi.

This activity is jointly provided by USF Health and touchIME. 

For further information visit our website: touchhaematologyime.org

Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered.

The experts

• Dr AeRang Kim, Children's National Hospital, Washington, DC, USA
• Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA
• Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA

This touchPODCAST is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Springworks  Therapeutics, Inc.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchoncologyime.org/expert-focus-management-of-nf1/

Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered.

The experts

• Dr AeRang Kim, Children's National Hospital, Washington, DC, USA
• Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA
• Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA

This touchPODCAST is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Springworks  Therapeutics, Inc.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchneurologyime.org/expert-focus-management-of-nf1/

• Dr Laura Mertens, Netherlands Cancer Institute, Amsterdam, The Netherlands
• Prof. Thomas Powles, Barts Cancer Centre, London, UK
• Ms Lindsay Diamond, Icahn School of Medicine at Mount Sinai, New York, NY, USA

This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website: 

www.touchONCOLOGY.com 

Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions.

The experts

• Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA
• Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
• Dr Teresa Amaral, Tübingen University, Tübingen, Germany

This touchPODCAST is for healthcare professionals outside of the UK only

This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. 

For further information visit our website:  https://touchdermaime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma

Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions.

The experts

• Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA
• Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
• Dr Teresa Amaral, Tübingen University, Tübingen, Germany

This touchPODCAST is for healthcare professionals outside of the UK only

This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. 

For further information visit our website:  https://touchoncologyime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma

Listen to Dr John Ladas, an expert in cataract surgery, as he answers a series of questions on intraocular lens power calculation, including how the use of artificial intelligence may help to improve accuracy, and provides an update on the latest advances in intraocular lens technology.

The expert

• Dr John Ladas, Maryland Eye Consultants & Surgeons, Silver Spring, MD, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Johnson & Johnson Surgical Vision, Inc. and Carl Zeiss Meditec, Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: www.touchophthalmology.com/

• Prof. Amy Paller - Northwestern University Feinberg School of Medicine, Chicago, IL, USA

This touchPODCAST is for HCPs outside the UK.  This activity is funded by an independent medical education grant from Chiesi USA Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchDERMA.com

Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis. 

The expert

Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchimmunologyime.org/Primary-biliary-cholangitis-therapeutic-landscape

Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis. 

The expert

Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchendocrinologyime.org/primary-biliary-cholangitis-therapeutic-landscape

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchONCOLOGY.com 

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchONCOLOGY.com 

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchRESPIRATORY.com

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchRESPIRATORY.com

What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.

The multidisciplinary team

Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands

Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands

Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.

The multidisciplinary team

Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA

Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.

The multidisciplinary team:

Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands

Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.

The multidisciplinary team

Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands

Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands

Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.

The multidisciplinary team

Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA

Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.

The multidisciplinary team:

Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands

Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

• Prof. Antoni Torres, University of Barcelona, Spain

This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website: 

www.touchINFECTIOUS DISEASES.com 

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

• Data reviews with Prof. Rosti
• Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below

Clinical themes

1. Approved and emerging TKIs for CML in the first-line setting
2. Approved and emerging TKIs for CML in the second- and later-line settings
3. Potential impact of emerging data on current and future clinical practice

The internationally renowned multiple myeloma expert faculty

• Prof. Gianantonio Rosti: Meldola, Italy
• Prof. Susanne Saussele: Mannheim, Germany
• Dr Carla Boquimpani: Rio de Janeiro, Brazil

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. 

For further information visit our website: TBC

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

• Data reviews with Prof. Rosti
• Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below

Clinical themes

1. Approved and emerging TKIs for CML in the first-line setting
2. Approved and emerging TKIs for CML in the second- and later-line settings
3. Potential impact of emerging data on current and future clinical practice

The internationally renowned multiple myeloma expert faculty

• Prof. Gianantonio Rosti: Meldola, Italy
• Prof. Susanne Saussele: Mannheim, Germany
• Dr Carla Boquimpani: Rio de Janeiro, Brazil

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. 

For further information visit our website: TBC

Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology. 

The experts

• Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA 
• Prof. Krista Lanctôt, University of Toronto, ON, Canada 
• Prof. James Galvin, University of Miami, FL, USA 

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Lundbeck. This activity is jointly provided by USF Health and touchIME in collaboration with the Gerontological Society of America (GSA).

For further information visit:

https://touchneurologyime.org/cme/curriculums/agitation-in-alzheimers-dementia/ 

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. The experts

• Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USA
• Prof. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium 

For further information visit our website: 

www.touchCARDIO.com 

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. The experts

• Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USA
• Prof. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium 

For further information visit our website: 

www.touchRESPIRATORY.com 

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchONCOLOGY.com 

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchONCOLOGY.com 

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchRESPIRATORY.com 

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchRESPIRATORY.com 

Listen to Dr Jennifer Carlisle, an expert in lung cancer, as she answers a series of questions on the targeted perioperative treatment strategies and best practices for patients with resectable and unresectable early-stage EGFR-mutant NSCLC. She also discusses how the evolving treatment landscape impacts biomarker testing and the importance of multidisciplinary care for optimizing outcomes in these patients.

The expert

Dr Jennifer Carlisle, Winship Cancer Institute of Emory University, Atlanta, GA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchoncology.org/EGFR-mutant-treatment-options-early-NSCLC 

Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice.

Overview

•       Data reviews with Prof. Mateos,
•       Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below

Clinical themes

1. Approved indications for BCMA-targeting agents,
2. New approaches to the use of existing BCMA-targeting agents,
3. Emerging BCMA-targeting agents

The internationally renowned multiple myeloma expert faculty

•       Prof. María-Victoria Mateos: Salamanca, Spain,
•       Dr Rakesh Popat: London, UK,
•       Prof. Evangelos Terpos: Athens, Greece

This touchPODCAST is for HCPs outside of the USA and UK only.

This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/bcma-mm-comy-eha-2024 

Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice.

Overview

•       Data reviews with Prof. Mateos,
•       Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below

Clinical themes

1. Approved indications for BCMA-targeting agents,
2. New approaches to the use of existing BCMA-targeting agents,
3. Emerging BCMA-targeting agents

The internationally renowned multiple myeloma expert faculty

•       Prof. María-Victoria Mateos: Salamanca, Spain,
•       Dr Rakesh Popat: London, UK,
•       Prof. Evangelos Terpos: Athens, Greece

This touchPODCAST is for HCPs outside of the USA and UK only.

This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:  https://touchhaematologyime.org/bcma-mm-comy-eha-2024

Listen to leading experts describe the pathophysiology of open-angle glaucoma and discuss how it is targeted by current and emerging treatment options, while providing insights on how different agents and combinations are used in practice.

The experts

• Angelo P Tanna, MD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA
• Courtney E Bovee, MD - Bovee Eye, Tampa Bay, FL, USA
• Joseph F Panarelli, MD - NYU Langone Eye Center, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Alcon Vision, LLC and is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchOPHTHALMOLOGY.com/

Listen to Prof. Diamant Thaçi in conversation with Dr Benjamin Ungar. They respond to questions submitted by the HCP audience and provide their expert insights regarding managing moderate–severe atopic dermatitis (AD) in children and adolescents, including assessing the severity of AD, selecting systemic therapy, and managing the potential side effects of systemic treatment.

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals and is jointly provided by USF Health and touchIME.

For further information visit our website: touchimmunology.com

Listen to Prof. Diamant Thaçi in conversation with Dr Benjamin Ungar. They respond to questions submitted by the HCP audience and provide their expert insights regarding managing moderate–severe atopic dermatitis (AD) in children and adolescents, including assessing the severity of AD, selecting systemic therapy, and managing the potential side effects of systemic treatment.

This touchPODCAST is for HCPs outside of the UK. 

This activity is funded by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals and is jointly provided by USF Health and touchIME.

For further information visit our website: touchderma.com

Listen to Prof. Barbara Burtness as she answers a series of questions focused on the evolving role of immune checkpoint inhibitors  in the first- and subsequent-line settings for recurrent/metastatic nasopharyngeal carcinoma. 

The expert

Prof. Barbara Burtness, Yale School of Medicine, New Haven, CT, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Coherus BioSciences. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/touchfocus_evolving-role-of-icis-in-rm-npc/

Pruritus in PBC and me: The patient experience

Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany  Patient Advocate – Mrs Collette Thain MBE PBC Foundation, Edinburgh, UK This touchPODCAST is for HCPs outside of the UK and USA only. This activity is funded by an independent medical education grant from GlaxoSmithKline Research & Development Ltd. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchendocrinologyime.org/mdt-cholestatic-pruritus-in-patients-with-pbc/

Pruritus in PBC and me: The patient experience

Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany  Patient Advocate – Mrs Collette Thain MBE PBC Foundation, Edinburgh, UK This touchPODCAST is for HCPs outside of the UK and USA only. This activity is funded by an independent medical education grant from GlaxoSmithKline Research & Development Ltd. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchdermatologyime.org/mdt-cholestatic-pruritus-in-patients-with-pbc/

Pruritus in PBC and me: The patient experience

Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany  Patient Advocate – Mrs Collette Thain MBE PBC Foundation, Edinburgh, UK This touchPODCAST is for HCPs outside of the UK and USA only. This activity is funded by an independent medical education grant from GlaxoSmithKline Research & Development Ltd. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchimmunologyime.org/mdt-cholestatic-pruritus-in-patients-with-pbc/

Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey.

Course director

Dr Helena Yu, Memorial Sloan Kettering Cancer Center New York, NY, USA

The clinical experts

Dr Aaron Lisberg, University of California Los Angeles (UCLA), Los Angeles, CA, USA

Dr Antonio Passaro, European Institute of Oncology, Milan, Italy

Dr Sara Pilotto, University of Verona, Verona, Italy

Ms Jackie Fenemore, Christie NHS Foundation Trust, Manchester, UK

Prof. Egbert Smit, Leiden University Medical Center, Leiden, The Netherlands and Netherlands Cancer Institute, Amsterdam, The Netherlands

Modules

Module 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC (timestamp: 0:00 - 32:33)

Module 2: EGFR-wildtype NSCLC: Advances in the treatment landscape (timestamp: 32:34 - 01:06:10)

Module 3: Bringing it together (timestamp: 01:06:10 - 01:43:40)

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:  

https://touchoncologyime.org/egfr-and-wildtype-late-stage-nsclc-management/

For further information visit our website:  https://touchrespiratoryime.org/egfr-and-wildtype-late-stage-nsclc-management

Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey.

Course director

Dr Helena Yu, Memorial Sloan Kettering Cancer Center New York, NY, USA

The clinical experts

Dr Aaron Lisberg, University of California Los Angeles (UCLA), Los Angeles, CA, USA

Dr Antonio Passaro, European Institute of Oncology, Milan, Italy

Dr Sara Pilotto, University of Verona, Verona, Italy

Ms Jackie Fenemore, Christie NHS Foundation Trust, Manchester, UK

Prof. Egbert Smit, Leiden University Medical Center, Leiden, The Netherlands and Netherlands Cancer Institute, Amsterdam, The Netherlands

Modules

Module 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC (timestamp: 0:00 - 32:33)

Module 2: EGFR-wildtype NSCLC: Advances in the treatment landscape (timestamp: 32:34 - 01:06:10)

Module 3: Bringing it together (timestamp: 01:06:10 - 01:43:40)

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:   https://touchoncologyime.org/egfr-and-wildtype-late-stage-nsclc-management/

Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.  

The experts

• Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA
• Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA
• Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchrespiratoryime.org/her2_in_solid_tumours_and_nsclc/

Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.  

The experts

• Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA
• Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA
• Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchoncologyime.org/her2_in_solid_tumours_and_nsclc/

Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice.

Overview 

• Data reviews with Dr McDonald
• Expert panel discussions with Dr McDonald, Prof. Bussel and Prof. Ghanima on the themes below

Clinical themes

1. How does ITP impact the patient and their quality of life?
2. What are the latest data that inform the use of current treatments for chronic ITP?
3. What data are there for emerging chronic ITP treatments and what do they tell us?

The internationally renowned ITP expert faculty

• Dr Vickie McDonald: London, UK
• Prof. James Bussel: New York, NY, USA,
• Prof. Waleed Ghanima: Oslo, Norway

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:   https://touchhaematologyime.org/itp-eha-isth-2024/ 

Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice.

Overview 

• Data reviews with Dr McDonald
• Expert panel discussions with Dr McDonald, Prof. Bussel and Prof. Ghanima on the themes below

Clinical themes

1. How does ITP impact the patient and their quality of life?
2. What are the latest data that inform the use of current treatments for chronic ITP?
3. What data are there for emerging chronic ITP treatments and what do they tell us?

The internationally renowned ITP expert faculty

• Dr Vickie McDonald: London, UK
• Prof. James Bussel: New York, NY, USA,
• Prof. Waleed Ghanima: Oslo, Norway

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:   https://touchoncologyime.org/itp-eha-isth-2024/

Listen to a panel of experts discuss the benefits of CGM in patients with T2D, strategies to overcome the barriers to its uptake and how to best support patients in implementing CGM.

The experts

• Prof. Stewart Harris, Western University,  London, Ontario, Canada,
• Dr Anders Carlson, International Diabetes Center at Park Nicollet, Minneapolis, MN, USA,
• Prof. Shannon Idzik, University of Maryland School of Nursing, Baltimore, MD, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Abbott Diabetes Care Inc. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:  www.touchENDOCRINOLOGY.com 

Listen to Prof. Hans Hammers as he answers a series of questions on the application of prognostic markers and clinical data within the multidisciplinary team to personalize care for patients with early stage through to advanced and metastatic RCC. In addition, he responds to questions on the use of effective communication strategies and shared decision-making when managing diverse and/or underserved populations with RCC.

The expert

• Prof. Hans Hammers, UT Southwestern, Dallas, TX, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/personalizing-care-multidisciplinary-team-renal-cell-carcinoma/

Listen to a conversation between Dr Christoph Boesecke and Dr Tristan Barber, two experts on HIV practising in Germany and the UK. They respond to questions submitted by the HCP audience and provide their insights on best practices for antiretroviral therapy selection for people living with HIV.

The experts

• Dr Christoph Boesecke – University of Bonn, Bonn, Germany
• Dr Tristan Barber – Royal Free London NHS Foundation Trust, London, UK

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical educational grant from ViiV Healthcare. This activity is provided by touchIME.

For further information visit our website:

https://touchinfectiousdiseases.com/education/hiv-art-selection-shared-decision-making/

Listen to a panel of leading experts discuss thyroid eye disease, including the underlying mechanisms, risk factors, symptomatology and burden of disease in affected patients, as well as the process for screening and diagnosing the disease.

The experts

• Dr Andrea Kossler, Stanford University School of Medicine, Palo Alto, CA, USA
• Dr Mario Salvi, University of Milan, Milan, Italy
• Dr Edsel Ing, University of Alberta, Edmonton and University of Toronto, Ontario, Canada

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Horizon Therapeutics and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit:

https://touchophthalmologyime.org/thyroid-eye-disease-an-evolving-continuum-of-care/

Listen to a panel of leading experts discuss thyroid eye disease, including the underlying mechanisms, risk factors, symptomatology and burden of disease in affected patients, as well as the process for screening and diagnosing the disease. 

The experts

• Dr Andrea Kossler, Stanford University School of Medicine, Palo Alto, CA, USA
• Dr Mario Salvi, University of Milan, Milan, Italy
• Dr Edsel Ing, University of Alberta, Edmonton and University of Toronto, Ontario, Canada

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Horizon Therapeutics and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit:

https://touchendocrinologyime.org/thyroid-eye-disease-an-evolving-continuum-of-care/

A thrombosis and haemostasis expert shares insights into reversal strategies for patients with direct oral anticoagulant-associated intracranial haemorrhage (DOAC-ICH), including benefits and risks of DOAC use, evidence for DOAC reversal agents and guideline-directed management of the condition. 

The expert

• Prof. Dr. med. Jan Beyer-Westendorf, University Hospital Carl Gustav Carus, Dresden, Germany

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: www.touchneurology.com

A thrombosis and haemostasis expert shares insights into reversal strategies for patients with direct oral anticoagulant-associated intracranial haemorrhage (DOAC-ICH), including benefits and risks of DOAC use, evidence for DOAC reversal agents and guideline-directed management of the condition. 

The expert

• Prof. Dr. med. Jan Beyer-Westendorf, University Hospital Carl Gustav Carus, Dresden, Germany

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: www.touchCARDIO.com 

Listen to Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment across various cancer types.

The expert

• Dr Dana Chase - UCLA Health, Los Angeles, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. 

For further information visit our website: https://touchoncologyime.org/

The experts

• Prof. Aleš Linhart, Charles University and General University Hospital, Prague, Czech Republic
• Dr Eric Wallace, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
• Prof. William Wilcox, Emory University School of Medicine, Atlanta, GA, USA

This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchENDOCRINOLOGY.com 

The experts

• Prof. Aleš Linhart, Charles University and General University Hospital, Prague, Czech Republic
• Dr Eric Wallace, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
• Prof. William Wilcox, Emory University School of Medicine, Atlanta, GA, USA

This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchCARDIO.com 

Listen to three leading Fabry disease experts discuss early diagnosis, organ monitoring, long-term individualized care and future directions.

The experts

• Prof. Aleš Linhart, Charles University and General University Hospital, Prague, Czech Republic
• Dr Eric Wallace, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
• Prof. William Wilcox, Emory University School of Medicine, Atlanta, GA, USA

This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: 

www.touchNEUROLOGY.com

Listen to leading experts describe the HIV life cycle, the rationale for multidrug antiretroviral therapy (ART) regimens, mechanisms of ART resistance and how to manage it in people living with HIV.

The experts

• Prof. Anne-Mieke Vandamme - Katholieke Universiteit Leuven, Belgium
• Prof. José Arribas - La Paz Hospital, Madrid, Spain
• Prof. Antonella Castagna - Vita-Salute San Raffaele University, Milan, Italy

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Viiv Healthcare. This activity is provided by touchIME.

For further information visit our website: 

https://touchinfectiousdiseases.com/education/demystifying-virology-the-link-between-the-hiv-life-cycle-and-art/

Listen to Ms Nikolina Dodlek, an oncology nurse from Croatia, in conversation with Professor Sherko Kümmel, a leading medical oncologist from Germany. They respond to questions submitted by the HCP audience and provide their expert insights on the use of HER2-directed antibody–drug conjugates (ADCs) in the treatment of patients with breast cancer.

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Daiichi Sankyo Europe GmbH and AstraZeneca. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/knowledge-for-nurses-adc-updates-in-breast-cancer

Listen to a panel of leading experts discuss the latest evidence and clinical implications of recently approved treatments for relapsed/refractory follicular lymphoma (R/R FL), the importance of shared decision-making in treatment selection in the era of BsAb and CAR T-cell therapies, and the key considerations for treatment sequencing. 

The experts

• Dr Matthew Lunning, University of Nebraska, Omaha, NE, USA,
• Professor Charalambos Andreadis, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA,
• Dr Tara Graff, Mission Cancer and Blood, Des Moines, IA, USA.

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.

For further information visit: https://touchoncologyime.org/evolving-treatment-paradigm-relapsed-refractory-follicular-lymphoma 

Listen to a panel of leading experts discuss the latest evidence and clinical implications of recently approved treatments for relapsed/refractory follicular lymphoma (R/R FL), the importance of shared decision-making in treatment selection in the era of BsAb and CAR T-cell therapies, and the key considerations for treatment sequencing. 

The experts

• Dr Matthew Lunning, University of Nebraska, Omaha, NE, USA,
• Professor Charalambos Andreadis, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA,
• Dr Tara Graff, Mission Cancer and Blood, Des Moines, IA, USA.

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.

For further information visit: https://touchhaematologyime.org/evolving-treatment-paradigm-relapsed-refractory-follicular-lymphoma

Listen to a medical oncologist and a pathologist as they discuss HER2 alterations in non-small cell lung cancer (NSCLC), including the different types of HER2 alterations, key considerations for HER2 testing and the latest data for HER2-targeting treatments. 

The experts

• Prof. Enriqueta Felip - Medical Oncologist, Vall d'Hebron University Hospital, Barcelona, Spain
• Prof. Keith Kerr - Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, UK

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchrespiratoryime.org/her2_nsclc_testing_and_targeted_therapies/

Listen to a medical oncologist and a pathologist as they discuss HER2 alterations in non-small cell lung cancer (NSCLC), including the different types of HER2 alterations, key considerations for HER2 testing and the latest data for HER2-targeting treatments. 

The experts

• Prof. Enriqueta Felip - Medical Oncologist, Vall d'Hebron University Hospital, Barcelona, Spain
• Prof. Keith Kerr - Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, UK

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchoncologyime.org/her2_nsclc_testing_and_targeted_therapies/

Listen to a neurologist and a neuro-ophthalmologist, both renowned experts in neuromyelitis optica spectrum disorder (NMOSD), answer questions from the ophthalmology and neurology communities on the management of NMOSD. They discuss presenting symptoms, differential diagnoses, management of acute attacks and long-term treatment.

The experts:

• Prof. John Chen - Mayo Clinic, Rochester, MN, USA
• Prof. Friedemann Paul - Charité - Universitätsmedizin Berlin, Campus Mitte, Germany

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Horizon Therapeutics. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchneurologyime.org/nmosd_diagnosis_treatment https://touchneurologyime.org/nmosd_diagnosis_treatment

Listen to a neurologist and a neuro-ophthalmologist, both renowned experts in neuromyelitis optica spectrum disorder (NMOSD), answer questions from the ophthalmology and neurology communities on the management of NMOSD. They discuss presenting symptoms, differential diagnoses, management of acute attacks and long-term treatment.

The experts:

• Prof. John Chen - Mayo Clinic, Rochester, MN, USA
• Prof. Friedemann Paul - Charité - Universitätsmedizin Berlin, Germany

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Horizon Therapeutics. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchophthalmologyime.org/nmosd_diagnosis_treatment https://touchneurologyime.org/nmosd_diagnosis_treatment

Listen to an HLH specialist and a paediatric intensivist discuss the clinical features of HLH in patients and when it is important to have a high index of suspicion of HLH.

The multidisciplinary team

• HLH specialist: Prof. Michael Jordan, Cincinnati, OH, USA
• Paediatric intensivist: Dr Kate Kernan, Pittsburgh, PA, USA

This touchPODCAST is for healthcare professionals in the USA only.

This activity is funded by an unrestricted independent medical education grant from Sobi Inc. This activity is jointly provided by USF Health and touchIME.

Listen to an HLH specialist and a pathologist discuss the role of the pathologist in the diagnostic workup of patients suspected of having HLH, including the insights available from bone marrow biopsy in identifying triggers for HLH.

The multidisciplinary team

• HLH specialist: Prof. Michael Jordan, Cincinnati, OH, USA
• Pathologist: Dr Eric Gars, Gainesville, FL, USA

This touchPODCAST is for healthcare professionals in the USA only.

This activity is funded by an unrestricted independent medical education grant from Sobi Inc. This activity is jointly provided by USF Health and touchIME

Listen to an HLH specialist, paediatric intensivist and critical care pharmacist discuss the importance of an individualized approach to the treatment of HLH, particularly when considering the age of the patient. 

The multidisciplinary team

• HLH specialist: Prof. Michael Jordan, Cincinnati, OH, USA
• Paediatric intensivist: Dr Kate Kernan, Pittsburgh, PA, USA
• Critical care pharmacist: Prof. Rob MacLaren, Denver, CO

This touchPODCAST is for healthcare professionals in the USA only.

This activity is funded by an unrestricted independent medical education grant from Sobi Inc. This activity is jointly provided by USF Health and touchIME.

Listen to an HLH specialist and a paediatric intensivist discuss the standard of care for patients with primary HLH and highlight the introduction of novel agents for second-line therapy for patients who do not respond in the first line.

The multidisciplinary team

• HLH specialist: Prof. Michael Jordan, Cincinnati, OH, USA
• Paediatric intensivist: Dr Kate Kernan, Pittsburgh, PA, USA

This touchPODCAST is for healthcare professionals in the USA only.

This activity is funded by an unrestricted independent medical education grant from Sobi Inc. This activity is jointly provided by USF Health and touchIME.

Listen to an HLH specialist and a paediatric intensivist discuss the clinical features of HLH in patients and when it is important to have a high index of suspicion of HLH.

The multidisciplinary team

• HLH specialist: Prof. Michael Jordan, Cincinnati, OH, USA
• Paediatric intensivist: Dr Kate Kernan, Pittsburgh, PA, USA

This touchPODCAST is for healthcare professionals in the USA only.

This activity is funded by an unrestricted independent medical education grant from Sobi Inc. This activity is jointly provided by USF Health and touchIME.

Listen to an HLH specialist and a pathologist discuss the role of the pathologist in the diagnostic workup of patients suspected of having HLH, including the insights available from bone marrow biopsy in identifying triggers for HLH.

The multidisciplinary team

• HLH specialist: Prof. Michael Jordan, Cincinnati, OH, USA
• Pathologist: Dr Eric Gars, Gainesville, FL, USA

This touchPODCAST is for healthcare professionals in the USA only.

This activity is funded by an unrestricted independent medical education grant from Sobi Inc. This activity is jointly provided by USF Health and touchIME.

Listen to an HLH specialist, paediatric intensivist and critical care pharmacist discuss the importance of an individualized approach to the treatment of HLH, particularly when considering the age of the patient. 

The multidisciplinary team

• HLH specialist: Prof. Michael Jordan, Cincinnati, OH, USA
• Paediatric intensivist: Dr Kate Kernan, Pittsburgh, PA, USA
• Critical care pharmacist: Prof. Rob MacLaren, Denver, CO

This touchPODCAST is for healthcare professionals in the USA only.

This activity is funded by an unrestricted independent medical education grant from Sobi Inc. This activity is jointly provided by USF Health and touchIME.

Listen to an HLH specialist and a paediatric intensivist discuss the standard of care for patients with primary HLH and highlight the introduction of novel agents for second-line therapy for patients who do not respond in the first line.

The multidisciplinary team

• HLH specialist: Prof. Michael Jordan, Cincinnati, OH, USA
• Paediatric intensivist: Dr Kate Kernan, Pittsburgh, PA, USA

This touchPODCAST is for healthcare professionals in the USA only.

This activity is funded by an unrestricted independent medical education grant from Sobi Inc. This activity is jointly provided by USF Health and touchIME.

Listen to Dr Carolyn Clevenger, a gerontological nurse practitioner, in conversation with family care partner Ms Kathleen Rhyne. They respond to questions submitted by the HCP audience, providing valuable insights on agitation in Alzheimer’s dementia with a focus on prevalence, behavioural symptoms and the importance of early recognition and diagnosis.

This touchPODCAST is for healthcare professionals outside of the UK only.

This activity is funded by an unrestricted independent medical education grant from Lundbeck. This activity is jointly provided by USF Health and touchIME in collaboration with the Gerontological Society of America (GSA).

For further information visit our website: https://touchneurology.com/education/mdt-perspectives-on-management-of-agitation-in-alzheimers-dementia/in-conversation-lets-talk-about-AAD/

Listen to a panel of leading experts—a renowned allergist, dermatologist, and haemato-oncologist—discuss the diagnosis and management of systemic mastocytosis, including current and emerging treatment options and multidisciplinary approaches to optimize patient care.

The experts

• Prof. Dr Vito Sabato, University of Antwerp, Antwerp, Belgium
• Dr Sigurd Broesby-Olsen, Odense University Hospital, Odense, Denmark
• Prof. Prithviraj Bose, MD Anderson Cancer Center University of Texas, TX, USA

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Blueprint Medicines and is jointly provided by USF Health and touchIME. 

For further information visit:  https://touchoncologyime.org/mdt-insights-systemic-mastocytosis

Listen to a panel of leading experts—a renowned allergist, dermatologist, and haemato-oncologist—discuss the diagnosis and management of systemic mastocytosis, including current and emerging treatment options and multidisciplinary approaches to optimize patient care.

The experts

• Prof. Dr Vito Sabato, University of Antwerp, Antwerp, Belgium
• Dr Sigurd Broesby-Olsen, Odense University Hospital, Odense, Denmark
• Prof. Prithviraj Bose, MD Anderson Cancer Center University of Texas, TX, USA

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Blueprint Medicines and is jointly provided by USF Health and touchIME. 

For further information visit:  https://touchhaematologyime.org/mdt-insights-systemic-mastocytosis

Listen to a panel of leading experts—a renowned allergist, dermatologist, and haemato-oncologist—discuss the diagnosis and management of systemic mastocytosis, including current and emerging treatment options and multidisciplinary approaches to optimize patient care.

The experts

• Prof. Dr Vito Sabato, University of Antwerp, Antwerp, Belgium
• Dr Sigurd Broesby-Olsen, Odense University Hospital, Odense, Denmark
• Prof. Prithviraj Bose, MD Anderson Cancer Center University of Texas, TX, USA

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Blueprint Medicines and is jointly provided by USF Health and touchIME. 

For further information visit:  https://touchdermaime.org/mdt-insights-systemic-mastocytosis

Listen to a panel of leading experts a renowned allergist, dermatologist, and haemato-oncologist discuss the diagnosis and management of systemic mastocytosis, including current and emerging treatment options and multidisciplinary approaches to optimize patient care.

The experts

• Prof. Dr Vito Sabato, University of Antwerp, Antwerp, Belgium
• Dr Sigurd Broesby-Olsen, Odense University Hospital, Odense, Denmark
• Prof. Prithviraj Bose, MD Anderson Cancer Center University of Texas, TX, USA

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Blueprint Medicines and is jointly provided by USF Health and touchIME. 

For further information visit:  https://touchimmunologyime.org/mdt-insights-systemic-mastocytosis

The expert

• Prof. Heather A Wakelee – Stanford University, CA, USA

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Merck & Co., Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchrespiratoryime.org/io-early-stage-nsclc/ 

The expert

• Prof. Heather A Wakelee – Stanford University, CA, USA

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Merck & Co., Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/io-early-stage-nsclc/

Listen to experts Prof. Karin Blakemore, Prof. Klaus Mohnike, Prof. Janet Legare and patient advocate Carly Kutner provide their insights on the impact of pharmacotherapies for achondroplasia

The multidisciplinary team and patient advocate:

MFM specialist - Prof. Karin Blakemore Johns Hopkins University School of Medicine, Baltimore, MD, USA

Paediatric endocrinologist - Prof. Dr. med. Klaus Mohnike  Otto-von-Guericke University Magdeburg, Magdeburg, Germany  

Paediatrician - Prof. Janet Legare University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Patient advocate - Ms Carly Kutner Freehold, NJ, USA

This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from BioMarin Pharmaceutical Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchendocrinologyime.org/mdt-diagnosis-monitoring-early-treatment-in- achondroplasia/